🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

ATG Individualized Dosing Model in URD-PBSCT.

RecruitingPhase 2Ages 14 Years - 65 YearsAllChinese PLA General Hospital
NCT06572462 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Anti-thymocyte globulin (ATG) is widely used in allogeneic hematopoietic stem cell transplantation to prevent severe graft-versus-host disease (GVHD) and graft failure. However, overexposure to ATG may increase cytomegalovirus (CMV), Epstein-Barr virus (EBV) reactivation, non-relapse mortality, and disease recurrence. A targeted dosing strategy was established based on ATG concentration monitoring and conducted a phase 2 trial to evaluate the safety and efficacy of the dosing strategy in adult unmanipulated haplo-PBSCT, a encouraging result was attained. In this trial, The ATG-targeted dosing strategy was extended to adult unrelated donor allogeneic hematopoietic stem cell transplantation, ATG was administered for 4 days (-5 days to -2 days) during conditioning. The ATG doses on-3 days and- 2days were adjusted by our dosing strategy to achieve the optimal ATG exposure. The primary endpoi

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Patients with malignant hematological tumors who have indications for allogeneic hematopoietic stem cell transplantation. 2. HLA-matched unrelated donor 3. Patient age ≥14 years old and ≤65 years old 4. ALT and AST ≤ 2.5 times the upper limit of normal values, bilirubin ≤ 2 times the upper limit of normal values 5. Creatinine ≤ high limit of normal value 6. No uncontrollable infection or serious mental illness 7. Physical strength score is 0-2 (ECOG) 8. Sign the informed consent form Exclusion Criteria: 1. Unrelated donor who is not HLA matched 2. No indication for allogeneic hematopoietic stem cell transplantation 3. Patient age \<14 years old or \>65 years old 4. The donor or recipient are pregnant 5. Suffering from mental illness or other conditions and being unable to proceed as planned
💊

What it tests

  • individualized ATG dosing strategy
📍

Where

1 site
Department of Hematology, First Medical Center of Chinese PLA General Hospital
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy